Harbin Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 5/6
Harbin Pharmaceutical Group has a total shareholder equity of CN¥5.8B and total debt of CN¥2.0B, which brings its debt-to-equity ratio to 34.4%. Its total assets and total liabilities are CN¥14.2B and CN¥8.5B respectively. Harbin Pharmaceutical Group's EBIT is CN¥745.6M making its interest coverage ratio -118.4. It has cash and short-term investments of CN¥3.2B.
Key information
34.4%
Debt to equity ratio
CN¥1.98b
Debt
| Interest coverage ratio | -118.4x |
| Cash | CN¥3.18b |
| Equity | CN¥5.76b |
| Total liabilities | CN¥8.48b |
| Total assets | CN¥14.24b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: 600664's short term assets (CN¥10.6B) exceed its short term liabilities (CN¥8.0B).
Long Term Liabilities: 600664's short term assets (CN¥10.6B) exceed its long term liabilities (CN¥447.7M).
Debt to Equity History and Analysis
Debt Level: 600664 has more cash than its total debt.
Reducing Debt: 600664's debt to equity ratio has increased from 8% to 34.4% over the past 5 years.
Debt Coverage: 600664's debt is well covered by operating cash flow (24.8%).
Interest Coverage: 600664 earns more interest than it pays, so coverage of interest payments is not a concern.